| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
22,041,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cognition Therapeutics is a clinical-stage biopharmaceutical company. Co. is developing a pipeline of small molecule product candidates that are designed to target the o-2 (sigma-2) receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer's disease, dry Age-Related Macular Degeneration (AMD), geographic atrophy (a form of dry AMD), and other conditions. Co.'s main product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Co. is initially focused on the development of CT1812 for the treatment of AD by targeting the accumulation of B-amyloid.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
5,700 |
5,700 |
5,700 |
3,214,328 |
| Total Buy Value |
$9,975 |
$9,975 |
$9,975 |
$3,951,055 |
| Total People Bought |
1 |
1 |
1 |
5 |
| Total Buy Transactions |
1 |
1 |
1 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ricciardi Lisa |
CEO & President |
• • – |
2024-03-14 |
4 |
B |
$1.75 |
$9,975 |
D/D |
5,700 |
291,345 |
2.81 |
- |
|
| Caggiano Anthony |
Chief Medical Officer |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
141,629 |
|
- |
|
| Doyle John Brendan |
Chief Financial Officer |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
129,824 |
|
- |
|
| Ricciardi Lisa |
CEO & President |
• • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
285,645 |
|
- |
|
| Caggiano Anthony |
Chief Medical Officer |
• – – |
2024-02-03 |
4 |
D |
$2.29 |
$29,259 |
D/D |
(12,777) |
81,629 |
|
- |
|
| Ricciardi Lisa |
CEO & President |
• • – |
2024-02-03 |
4 |
D |
$2.29 |
$63,726 |
D/D |
(27,828) |
210,645 |
|
- |
|
| Bios Equity Cof, Lp |
Director |
– • • |
2023-11-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
500,095 |
|
- |
|
| Bp Directors, Lp |
Director |
– • • |
2023-11-08 |
4 |
A |
$1.05 |
$525,100 |
I/I |
500,095 |
500,095 |
|
- |
|
| Bios Fund Ii Qp, Lp |
Director |
– • • |
2023-11-08 |
4 |
A |
$1.05 |
$525,100 |
I/I |
500,095 |
500,095 |
|
- |
|
| Richstone Ellen B |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,000 |
|
- |
|
| Khattar Jack A. |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
|
- |
|
| Wallace Peggy |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
43,961 |
|
- |
|
| Monia Brett P |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
|
- |
|
| Bios Fund Ii Qp, Lp |
Director |
– • • |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
|
- |
|
| Bios Fund Iii Nt, Lp |
Director |
– • • |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
I/I |
6,000 |
6,000 |
|
- |
|
| Doyle John Brendan |
Chief Financial Officer |
• – – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
109,824 |
109,824 |
|
- |
|
| Ricciardi Lisa |
CEO & President |
• • – |
2023-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
213,973 |
238,473 |
|
- |
|
| Caggiano Anthony |
Chief Medical Officer |
• – – |
2023-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
94,406 |
94,406 |
|
- |
|
| Richstone Ellen B |
Director |
– • – |
2022-11-29 |
4 |
B |
$2.66 |
$26,550 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Bios Fund Iii Nt, Lp |
Director |
– • • |
2022-11-28 |
4 |
B |
$2.65 |
$42,565 |
I/I |
16,064 |
309,748 |
2.25 |
- |
|
| Bios Fund Ii Qp, Lp |
Director |
– • • |
2022-11-28 |
4 |
B |
$2.65 |
$42,565 |
I/I |
16,064 |
309,748 |
2.25 |
- |
|
| Bios Fund Ii Qp, Lp |
10% Owner |
– – • |
2022-11-16 |
4 |
B |
$1.40 |
$99,400 |
I/I |
71,000 |
307,877 |
1.5 |
- |
|
| Bios Fund Iii Nt, Lp |
10% Owner |
– – • |
2022-11-16 |
4 |
B |
$1.40 |
$99,400 |
I/I |
71,000 |
307,877 |
1.5 |
- |
|
| Bios Fund Iii Nt, Lp |
10% Owner |
– – • |
2022-11-15 |
4 |
B |
$1.20 |
$1,800,000 |
I/I |
1,500,000 |
299,608 |
1.5 |
- |
|
| Ricciardi Lisa |
CEO & President |
• • – |
2022-11-15 |
4 |
B |
$1.30 |
$15,600 |
D/D |
12,000 |
24,500 |
2.81 |
- |
|
52 Records found
|
|
Page 1 of 3 |
|
|
